The RASP Modulator Platform

Doctor speaking with a man across her desk
Our innovative RASP modulator platform represents a revolutionary approach to pharmacology. Unlike traditional drugs that target specific proteins, our platform targets a family of small protein-binding molecules, allowing us to influence the activity and structure of multiple proteins simultaneously. The RASP-targeting approach has the potential to down-regulate pro-inflammatory systems or groups of proteins, and may lead to multiple beneficial clinical effects while avoiding toxicity associated with single-target inhibition or activation.

Currently, we’re advancing the development of other novel RASP modulators to treat RASP-associated diseases. Our variety of small molecules are designed to bind and facilitate the degradation of RASP, thereby preventing RASP-associated inflammation and toxicity. Our flagship product candidate, reproxalap, has demonstrated rapid and broad-based activity in treating dry eye disease, with a consistent safety profile observed across multiple late-stage clinical trials.

In laboratory studies, reproxalap has been observed to effectively trap and degrade RASP, without directly affecting receptors, enzymes, ions channels, or other proteins. Drug-RASP adducts are rapidly broken down within cellular environments, leading to undetectable levels of both reproxalap and RASP.

By forming covalent drug-RASP adducts that undergo degradation, our RASP modulators have the potential to treat immune-mediated and metabolic diseases by reducing RASP levels.